AVEO Pharmaceuticals, Inc. (AVEO) Receives Consensus Recommendation of “Buy” from Analysts

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has been given a consensus rating of “Buy” by the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $6.33.

A number of analysts recently commented on AVEO shares. BidaskClub upgraded AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 11th. HC Wainwright set a $9.00 target price on AVEO Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research lowered AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 23rd. Finally, National Securities lowered AVEO Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday.

In related news, major shareholder Equity Opportunities Iv Growth bought 663,716 shares of the firm’s stock in a transaction dated Tuesday, August 21st. The stock was bought at an average cost of $2.26 per share, for a total transaction of $1,499,998.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.40% of the stock is currently owned by insiders.

Several institutional investors have recently bought and sold shares of AVEO. BlackRock Inc. grew its position in shares of AVEO Pharmaceuticals by 271.9% during the 2nd quarter. BlackRock Inc. now owns 6,977,746 shares of the biopharmaceutical company’s stock worth $15,770,000 after buying an additional 5,101,281 shares during the period. NEA Management Company LLC lifted its holdings in shares of AVEO Pharmaceuticals by 8.7% during the 2nd quarter. NEA Management Company LLC now owns 17,783,722 shares of the biopharmaceutical company’s stock valued at $40,091,000 after purchasing an additional 1,421,028 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of AVEO Pharmaceuticals by 396.0% during the 2nd quarter. Northern Trust Corp now owns 1,098,075 shares of the biopharmaceutical company’s stock valued at $2,482,000 after purchasing an additional 876,703 shares in the last quarter. Fosun International Ltd bought a new position in shares of AVEO Pharmaceuticals during the 3rd quarter valued at about $1,090,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of AVEO Pharmaceuticals by 279.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 288,073 shares of the biopharmaceutical company’s stock valued at $651,000 after purchasing an additional 212,059 shares in the last quarter. Institutional investors own 50.84% of the company’s stock.

Shares of AVEO stock opened at $1.86 on Friday. The stock has a market capitalization of $241.63 million, a P/E ratio of -11.63 and a beta of 2.00. AVEO Pharmaceuticals has a 12 month low of $1.78 and a 12 month high of $3.59.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.09). The company had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $1.35 million. Analysts anticipate that AVEO Pharmaceuticals will post -0.25 EPS for the current year.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Story: What is the Dividend Aristocrat Index?

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply